Table 5. Toxicities of patients with R/SP-MLNMs treated with SRT.

	Group A, n (%)				Group B, n (%)				Total, n (%)
Acute toxicities	Any Grade	Grade 3	Grade 4	Grade 5	Any Grade	Grade 3	Grade 4	Grade 5	Any Grade	Grade 3	Grade 4	Grade 5
Pneumonitis	0	0	0	0	1 (6)	0	0	0	1 (3)	0	0	0
Esophagitis	1 (6)	0	0	0	1 (6)	1 (6)	0	0	3 (9)	1 (3)	0	0
Tracheitis	0	0	0	0	2 (12)	2 (12)	0	0	2 (6)	2 (6)	0	0
Chest pain	0	0	0	0	1 (6)	0	0	0	1 (3)	0	0	0
Agranulocytosis	0	0	0	0	1 (6)	0	0	0	1 (3)	0	0	0
Thrombocytopenia	0	0	0	0	1 (6)	0	0	0	1 (3)	0	0	0
Late toxicities
Tachycardia	0	0	0	0	1 (6)	0	0	0	1 (3)	0	0	0
Lung fibrosis	0	0	0	0	1 (6)	0	0	0	1 (3)	0	0	0
Tracheoesophageal fistula	0	0	0	0	1 (6)	0	0	1 (6)	1 (3)	0	0	1 (3)
Esophageal-mediastinal fistula	0	0	0	0	1 (6)	0	0	1 (6)	1 (3)	0	0	1 (3)

Note: Group A: Patients with R/SP-MLNMs who received treatment including surgery and/or chemotherapy, but not radiation therapy; Group B: Patients with R/SP-MLNMs who received treatment including surgery and/or chemotherapy, and radiation therapy

Percent was calculated based on the total enrolled in each group (group A = 16, group B = 17) or the total study (33).